Clinical trial

Weight Loss Management in Endometrial Cancer Survivors

Active, not recruiting · Not applicable · 1 countries · Registry ID NCT06877572

Active, not recruitingNot applicableObservational

What this study is about

This study is being done to understand how oncologists can engage a multidisciplinary team to help endometrial cancer survivors with obesity to engage in a weight management program and potentially start a weight loss medication. Obesity often impacts the future health and longevity of early-stage endometrial cancer survivors more than their cancer diagnosis. Patients will be referred to the KUMC OB/Gyn weight management clinic to discuss weight management options. * If patients decide to use medications for weight loss, then the study will collect data from their chart that is recorded as part of routine monitoring for patients on weight loss medications. * If patients decide not to use any medications, the study will monitor physical exam and lab data collected as part of their routine medical care. The study will also try to understand reasons why patients did or did not start using a weight loss medication.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed

SexFemale

Healthy volunteersNot accepted

ConditionEndometrial Cancer Survivors, Weight Management, Early Stage Endometrial Cancer

Full registry criteria

Inclusion Criteria: * ≥18 years old * ECOG 0-2 * BMI ≥ 30kg/m2 * Completed surgical staging with no evidence of residual disease * Endometrioid endometrial adenocarcinoma, p53 wild type * Stage 1 * Undergoing active surveillance +/- brachytherapy Exclusion Criteria: * Unable to participate in behavior weight loss * Stroke, heart attack, end stage liver disease, or end stage kidney disease during the last 6 months. * Currently on a GLP-1 agonist * Currently on insulin

Treatments and study arms

Weight loss with pharmacotherapy

Behavioral

Patients will meet with a weight management specialist and discuss their options for weight loss including medications (GLP-1 agonist, naltrexone/bupropion, orlistat, or phentermine/topiramate) or bariatric surgery.

Weight loss without pharmacotherapy

Behavioral

Participants not on medications will have their weight recorded at subsequent cancer surveillance or other routine medical visits

Primary outcomes

Percentage of participants referred to weight loss clinic who are able to start weight management medications12 months

We will track the number of participants who do and do not start medication. Patients will be offered GLP-1 agonist, naltrexone/bupropion, orlistat, or phentermine/topiramate based discussion with weight management specialist.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

University of Kansas Medical Center🇺🇸 Kansas City, Kansas, United States

Open map